2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 464

The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Abstract Number: 465

Seasonal Variation in Cutaneous Flares for Pediatric Lupus
Abstract Number: 466

Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
Abstract Number: 467

The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry
Abstract Number: 468

Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study
Abstract Number: 469

Clinical Characteristics and Treatment of 25 Children with Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy in China
Abstract Number: 470

Pro-Inflammatory High Density Lipoprotein Function Is Associated with Accelerated Carotid Intimal Medial Thickness Progression in Childhood-Onset SLE
Abstract Number: 471

Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus
Abstract Number: 472

Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications
Abstract Number: 473

A Weighty Diagnosis: Weight Change and Risk Factors in Early Juvenile Systemic Lupus Erythematosus
Abstract Number: 474

Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
Abstract Number: 475

Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 476

A Better Understanding of Childhood Sjögren Syndrome: Evaluation of the 2016 Acr/EULAR Classification Criteria for Use in Diagnosing Sjögren Syndrome in Children
Abstract Number: 477

Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
Abstract Number: 478

Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients: Results from the Paediatric Rheumatology International Trials Organisation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].